Needham & Company LLC reissued their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research note published on Friday morning, Benzinga reports. They currently have a $50.00 price objective on the stock. RYTM has been the subject of a number of other reports. Wells Fargo & Company boosted their target […]